Literature DB >> 27564970

Astragaloside IV attenuates inflammatory reaction via activating immune function of regulatory T-cells inhibited by HMGB1 in mice.

Jinfeng Li1, Lifeng Huang2, Shuzhen Wang1, Yongming Yao3, Zhenyu Zhang1.   

Abstract

CONTEXT: High-mobility group box 1 (HMGB1) protein is a highly abundant protein that can promote the pathogenesis of inflammatory. Some experiments have demonstrated a vital role for HMGB1 to modulate the immune function of regulatory T-cells (Tregs). Astragaloside IV (AST IV), an extract from Astragalus membranaceus Moench (Leguminosae), has been shown to exert potent cardioprotective and anti-inflammatory effects. It is still unclear whether AST IV has a latent effect on the proinflammatory ability of HMGB1 with subsequent activation of Tregs in vivo.
OBJECTIVE: This research explores the antagonism of different doses of AST IV on the immunologic function of Tregs mediated by HMGB1.
MATERIALS AND METHODS: Mouse models (BALB/c) were constructed by which normal saline or AST IV was administered i.p. at 2, 4 and 6 days after the administration i.p. of 20 μg recombinate HMGB1. Spleen was used to procure Treg and CD4 + CD25- T-cells which were co-cultured with Treg. Cell phenotypes of Tregs(Foxp3) were examined, and the cytokine levels in supernatants and the proliferation of T-cells were assayed. Gene expression was measured by RT-PCR.
RESULTS: (1) The expression levels of Foxp3 in Treg on post-stimulus days (PSD) 1-7 were significantly decreased in the HMGB1 group in comparison to those in the control group mice (p < 0.01). The Foxp3 expression was markedly increased in a dose-dependent manner in the AST group as compared with those in the HMGB1 group (p < 0.0 1-0.05). The same results were found in the contents of cytokines (IL-10 and TGF-β) released into supernatants by Treg. (2) When CD4 + CD25- T-cells were co-cultured with Treg stimulated by HMGB1, the cell proliferation and the levels of cytokines (IL-2 and IFN-γ) in supernatant were markedly increased as compared with those in the HMGB1 group. The level of IL-4 was markedly decreased as compared with that in the HMGB1 group. The same results were found when CD4 + CD25- T-cells were co-cultured with Treg in the NS group. Compared with those in the NS group, the contrary results were shown in a dose-dependent manner in the AST group. DISCUSSION AND
CONCLUSION: These results showed that AST IV has a therapeutic effect on inflammation promoted by HMGB1, and it should be studied as a new drug for the treatment of sepsis.

Entities:  

Keywords:  High mobility group box 1 protein; immunity; inflammation

Mesh:

Substances:

Year:  2016        PMID: 27564970     DOI: 10.1080/13880209.2016.1216133

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  7 in total

1.  Astragaloside IV sensitizes non-small cell lung cancer cells to cisplatin by suppressing endoplasmic reticulum stress and autophagy.

Authors:  Song-Tao Lai; Yan Wang; Fei Peng
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 3.005

Review 2.  Recent Advances in Herbal Medicines for Digestive System Malignancies.

Authors:  Jiyao Sheng; Xiaohan Zou; Ziqian Cheng; Yien Xiang; Wei Yang; Yang Lin; Ranji Cui
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

Review 3.  Evaluation of the Pharmaceutical Properties and Value of Astragali Radix.

Authors:  Amy G W Gong; Ran Duan; Huai Y Wang; Xiang P Kong; Tina T X Dong; Karl W K Tsim; Kelvin Chan
Journal:  Medicines (Basel)       Date:  2018-05-21

4.  Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats.

Authors:  Wei Liu; Guozhi Liu; Jing Liu
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

Review 5.  Anti-Aging Implications of Astragalus Membranaceus (Huangqi): A Well-Known Chinese Tonic.

Authors:  Ping Liu; Haiping Zhao; Yumin Luo
Journal:  Aging Dis       Date:  2017-12-01       Impact factor: 6.745

6.  QiShenYiQi pill attenuates atherosclerosis by promoting regulatory T cells, inhibiting T helper 17 cells and accelerating cholesterol excretion.

Authors:  Li Peng; Chong-Shan Lv; Yun Zhao; Shao-Dong Chen; Yang Huang; Da-Wei Lu; Shu-Qiong Huang; Zong-Bao Yang; Lin-Chao Qian; Lei Wen
Journal:  Oncotarget       Date:  2017-07-07

7.  Influence of astragaloside IV on pharmacokinetics of triptolide in rats and its potential mechanism.

Authors:  Jian Gao; Xiangmin Zeng; Wei Zhao; Desheng Chen; Jing Liu; Ning Zhang; Xingliang Duan
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.